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Objective: To explore the potential efficacy of multi-modular motion-
assisted memory desensitization and reprocessing (3MDR) in British
military veterans with treatment-resistant service-related PTSD.
Methods: Exploratory single-blind, randomized, parallel arm, cross-
over controlled trial with nested process evaluation to assess fidelity,
adherence and factors that influence outcome.
Results: A total of 42 participants (all male) were randomized with 83%
retention at 12 weeks and 86% at 26 weeks. The difference in mean
Clinician-Administered PTSD Scale for DSM-5 scores between the
immediate and delayed 3MDR arms was 9.38 (95% CI 17.33 to
1.44, P = 0.021) at 12 weeks and 3.59 (14.39 to 7.20, P = 0.513)
at 26 weeks when both groups had received 3MDR. The likely effect
size of 3MDR was found to be 0.65. Improvements were maintained at
26-week follow-up. 3MDR was found to be acceptable to most, but not
all, participants. Several factors that may impact efficacy and
acceptability of 3MDR were identified.
Conclusion: 3MDR is a promising new intervention for treatment-
resistant PTSD with emerging evidence of effect.
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Significant outcomes
• 3MDR reduced symptoms in male military veterans with treatment-resistant PTSD.
• 3MDR was well tolerated by most but not all participants.
• Improvements following 3MDR were maintained at three-month follow-up.
Limitations
• The sample size of 42 is relatively small.
• The results may not be generalizable to non-military veteran populations.
• The follow-up period was restricted to three months.
Introduction
The majority of those who serve in the armed forces
do well after they leave, but over 7% have post-trau-
matic stress disorder (PTSD) (1). Unfortunately,
many veterans remain symptomatic despite evi-
dence-based treatment and research suggest that
psychological treatments for PTSD may not be as
effective for veterans as for other populations (2, 3).
There is a clear need for more effective interventions.
Multi-modular motion-assisted memory desensitiza-
tion and reconsolidation (3MDR) (4) is a new treat-
ment that aims to reduce cognitive avoidance and
augment engagement with therapy. It is based on
known therapeutic principles of virtual reality expo-
sure therapy (5) and eye movement desensitization
and reprocessing (EMDR) (6), embedded in a novel
context in which the patient walks on a treadmill
whilst immersing in and interacting with a series of
self-selected images that are displayed on a large
screen. Preliminary research conducted by the origi-
nators of 3MDR has been promising (4), and there
is a need for further research to determine its true
potential for treatment-resistant PTSD.
Aims of the study
To explore the potential efficacy of multi-modular
motion-assisted memory desensitization and
reconsolidation further by determining whether it
is able to reduce traumatic stress symptoms in Bri-
tish military veterans with treatment-resistant ser-
vice-related PTSD, to a significantly greater degree
than a waiting list and to explore factors associated
with its feasibility.
Material and methods
Design
This was an exploratory single-blind, randomized,
parallel arm, cross-over, controlled trial with a one-
to-one allocation ratio and nested process evaluation
to assess fidelity, adherence and factors that influ-
ence outcome. The trial followed CONSORT guide-
lines (7) and was granted approval by the South
East Wales Research Ethics Committee. The trial
was conducted between July 2017 and July 2019.
Sample size
To detect a mean 15-point difference on the Clini-
cian-Administered PTSD Scale between 3MDR
and delayed 3MDR at a 0.05 confidence level and
80% power, assuming a standard deviation of
15.18, based on a previous study of PTSD treat-
ment, 17 subjects would be needed in each arm.
Allowing for a 20–25% drop-out, a total proposed
sample size of 42 was determined. For the qualita-
tive aspects, based on previous research (8), we
anticipated that interviews would be conducted with
around 10 purposively sampled participants,
selected to ensure the inclusion of those with a wide
range of therapy experiences, and all six therapists.
Inclusion/exclusion criteria
Wide eligibility criteria were used to ensure good
external validity. Participants were aged 18 or
over, provided informed consent, met DSM5 (9)
criteria for PTSD and had previously received
trauma-focused psychological treatment without
loss of PTSD diagnosis. Exclusion criteria were
psychosis, DSM5 severe depressive episode, sub-
stance dependence, change in psychotropic medi-
cation within one month, suicidal intent and
inability to walk for 30–45 min on a treadmill.
Individuals with comorbidity were included if
PTSD was considered the primary diagnosis.
Recruitment and consent
Potentially eligible British military veterans who
attended NHS clinics in South Wales were
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approached by clinicians involved in their care,
screened and then fully assessed by one of two
researchers after providing informed consent. If
individuals met the eligibility criteria, they were
randomized to receive 3MDR immediately or after
a delay of 12 weeks. A statistician used a computer
programme to generate randomization codes on a
1:1 basis with a block size of 6 and no stratifica-
tion. The codes were sealed in opaque brown
envelopes numbered from 1 to 42. The 3MDR lab-
oratory researcher (who was blind to their content)
opened the envelopes consecutively, advised the
participant of the arm they had been allocated to
and the date of their first 3MDR session.
Outcome measures
All outcome measures were administered by one of
two postgraduate researchers blind to randomiza-
tion allocation at baseline, 12 and 26 weeks after
randomization. The primary outcome was
symptoms of PTSD measured by the Clinician-
Administered PTSD Scale for DSM5 (CAPS5) (10),
a 29-item structured interview for assessing PTSD
diagnostic status and symptom severity and widely
considered the gold standard in PTSD assessment.
The researchers were trained in administration of
the CAPS5 and demonstrated good inter-rater
reliability with each other and with their trainers.
Regular discussions of the scoring of individual
items between the researchers and the lead author
(who was one of the trainers), along with indepen-
dent rating of training videos during the trial, were
used to maintain good inter-rater reliability
(Kappa = 0.74). Secondary outcome measures were
brief, well-validated self-report measures (PTSD
Checklist) (11) for traumatic stress; Work and
Social Adjustment Scale (WSAS) (12) for quality of
life/functional impairment; Patient Health Ques-
tionnaire-9 (PHQ-9) (13) for depression; General
Anxiety Disorder-7 (GAD-7) (14) for anxiety;
AUDIT-O (15) for alcohol use; and the Insomnia
Severity Index (ISI) (16) for sleep difficulties. In
addition, the Multidimensional Scale for Perceived
Social Support (17) was used to assess perceived
social support and changes in health-related quality
of life were measured by the EQ-5D-5L (18).
3MDR intervention
3MDR therapy was delivered weekly over nine
weeks (two weeks preparation, six weeks 3MDR
and one concluding session) by experienced psy-
chological therapists working with Veterans’ NHS
Wales. Therapists were extensively trained in
3MDR and supervised by its originators
throughout the trial. 3MDR sessions used the
Motek Gait Real-time Analysis Interactive Lab
(GRAIL) system at Cardiff University which uses
an instrumented dual-belt treadmill, a motion-cap-
ture system and synchronized virtual reality (VR)
environment, which comprises a 180° projection
screen with 4 projectors and a surround sound sys-
tem (see Figure S1). The 3MDR protocol involved
projection of purpose-built tunnels to walk in and
projection of self-selected digital pictures inte-
grated into the software used for treatment.
Prior to the 3MDR sessions, participants were
asked to select 12 pictures that evoked memories of
the traumatic event. The therapists guided the par-
ticipant to limit avoidance during picture selection.
Supported by the therapist, the pictures were
arranged according to 0–10 subjective units of dis-
tress (SUD) score and theme. For each session, a
maximum of seven digital pictures were used for
projection on the screen. Participants also chose
two pieces of music. The first for the warm-up walk
aimed to take the participant back to the time of
the trauma, for example music played a lot during
this period. The second, for the cool-down, aimed
to bring the participant back to the here and now.
During sessions, participants walked at their
preferred walking speed. The sessions started with
an introduction phase, in which participants saw
an outdoor pathway ahead and their music began
to play whilst verbal guidance prepared them for
the intervention phase. Participants entered a tun-
nel to approach their first picture whilst being
guided by instructions on what to do. As soon as
they saw their chosen picture, a literal description
of this was requested with a brief account of the
related memories, feelings and bodily sensations.
These were entered as key phrases so they became
visible on the screen. When participants confirmed
there were no more new feelings, the dual task was
started: a red ball moved across the screen from
left to right and back to create bilateral stimula-
tion. Whilst focusing on the phrases on the screen,
participants were asked to track the ball and call
out random numbers displayed on it. After 30–
45 s, the ball was removed, the image faded away,
and a SUD score was requested and recorded. The
tunnel then re-appeared, and the process was
repeated for the other pictures. After the last pic-
ture, the final phase began with their second
selected piece of music, assisting return to the here
and now, and positive feedback was given about
what had been achieved, to conclude the session.
After the platform phase, a therapist-led discus-
sion occurred to elicit how the session was and to
discuss the meaning of the re-experiencing to the
participant in this setting. The therapist ensured
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that the participant was completely returned to the
here and now and aimed to enable the participant
to attach a positive meaning to the 3MDR session.
Every 3MDR session was video-recorded, and a
report summarizing the behavioural response to
the intervention was produced. One session for
each participant was randomly selected and
checked for fidelity by either EV, MN or MvG
(three of the originators of 3MDR) using a scale
specifically developed by them and JIB for this
study. The raters independently rated the videos
assigned to them and discussed their ratings to
support inter-rater reliability. Further discussion
occurred if there were concerns about specific rat-
ings. The scale included items on the following:
supporting selection of pictures and music; educa-
tion about 3MDR; preparation for the session;
encouraging approach behaviour to selected
images; addressing hotspots; supporting narrative
unfolding; eliciting key physical, cognitive and
emotional associations; empowering participant
and encouraging togetherness; stimulating integra-
tion and postsession processing; and reflecting on
newly acquired memories, experiences and skills.
Analyses
Quantitative outcome data – all continuous out-
comes were analysed, by comparing means
between arms using ANCOVA, with the individ-
ual’s baseline scores as covariate, as well as age,
baseline PHQ-9 and time since trauma. All ran-
domized participants were considered for analyses
under the intention to treat principle. Sensitivity
analyses of CAPS-5 at 12 and 26 weeks were
undertaken via multiple imputation using random-
ized arm, baseline CAPS-5, age, baseline PHQ-9
and time since trauma as model covariates. The
number of imputations required was determined
from the proportion of missing CAPS-5 data at 12
and 26 weeks. All analyses were performed at the
end of the data collection period using SPSS ver-
sion 25 (19) and Stata/IC 15.1 (20).
Qualitative data – semistructured interviews
were audio-recorded and transcribed verbatim.
Transcripts were imported into QSR NVivo 10
(21) software for computer-aided qualitative data
analysis (CAQDA). Following a process of induc-
tive thematic analysis (22), interview data were
examined for recurring patterns found across dif-
ferent transcripts as well as for deviant cases, or
views and experiences found in single transcripts
only (23). The aim was to reveal the fullest range
of views and experiences. To ensure comprehen-
siveness and validity, a preliminary analysis was
shared and discussed with the research team.
Results
Quantitative
Fifty-two military veterans were referred to the
trial, and 42 participants (all male) were recruited
and randomized. The retention rate was 83% at
12 weeks and 86% at 26 weeks (see Fig. 1). The
primary traumatic events suffered were the follow-
ing: severe human suffering (11, 26.2%); serious
injury, harm or death you caused to someone (10,
23.8%); fire or explosion (9, 21.4%), combat or
exposure to a war zone, sudden violent death, sud-
den unexpected death of someone close to you and
missing data (all 2, 4.8%); and physical assault,
assault with a weapon, sexual assault and captivity
(e.g. kidnapping) (all 1, 2.4%). All participants
had tried at least one trauma-focused psychologi-
cal treatment, many had received both EMDR and
TFCBT, and the majority had also received other
psychological treatments, including CBT without a
trauma focus, supportive counselling and group
therapy. All participants had been treated with
medication in an attempt to reduce their PTSD
symptoms and had been under service military
mental health services and/or veterans mental
health services. The majority had been under men-
tal health services for many years.
Table 1 summarizes participants’ demographic
characteristics and allows comparison of those
randomized to immediate 3MDR and delayed
3MDR. The average age of participants was 42,
and time since their worst traumatic event was
over 19 years. The vast majority of participants
were White British (95%), around a third were
employed and a third unable to work. Almost half
the participants had a comorbid depressive disor-
der. The 3MDR sessions lasted on average 63.3
(SD 14.5) minutes. Participants walked an average
distance of 3.7 (SD 1.2) km on the treadmill per
session with an average speed of 0.99 (SD 0.21) m/
s; a relatively slow walking speed.
Table 2 provides data on the outcome measures
at baseline, 12 weeks and 26 weeks postrandom-
ization. Table 3 demonstrates statistically signifi-
cant greater improvement for participants in the
3MDR versus delayed 3MDR arm at the primary
outcome points of 12 weeks on the CAPS-5, PCL-
5, GAD-7 and ISI. There was no significant differ-
ence between the arms on WSAS, PHQ-9, EQ-5D-
5L, Audit-O and MSPSS.
There were no statistically significant differences
between the immediate and delayed 3MDR arms
at 26 weeks (after both had received 3MDR) with
the exception of the ISI (in favour of the immedi-
ate 3MDR arm) and the EQ-5D-5L (in favour of
the delayed 3MDR arm) (see Table S1). From the
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multiple imputation sensitivity analyses, the differ-
ence in mean CAPS-5 scores between the immedi-
ate and delayed 3MDR arms was 9.38 (95% CI
17.33 to 1.44, P = 0.021) at 12 weeks and
3.59 (14.39 to 7.20, P = 0.513) at 26 weeks. In
proportion with the number of cases missing the
outcome, 17 imputations were used for Week 12
and 15 for Week 26. Figure 2 illustrates the rela-
tive reductions in CAPS-5 scores over time
between the two arms. The likely effect size of
3MDR was found to be 0.65, representing a mod-
erate treatment effect (24).
Fidelity
Fidelity ratings of the therapy sessions were high.
All but one session viewed was felt to adhere to the
3MDR treatment protocol well. This session
involved a participant who was initially assessed as
able to walk on the treadmill but felt unable to do
so because of musculoskeletal issues and, there-
fore, sat behind the treadmill for the 3MDR ses-
sion.
Qualitative
Eleven purposively selected participants, all six
therapists and the researcher responsible for the
technical operation of 3MDR completed
semistructured interviews. Participants were
selected on an ongoing basis as the trial pro-
gressed. To learn from as wide a range of veterans
as possible, individuals with a range of characteris-
tics and experiences were recruited, including par-
ticipants judged to have accommodated both well
to 3MDR (e.g. participating in all sessions, voicing
Assessed for eligibility (n = 52)
Excluded (n = 10)
Not meeting inclusion criteria (n = 10)
Analysed  (n = 21)
Excluded from analysis (n = 0)
Lost to follow-up (4 unable to contact)
Discontinued intervention (n = 11; 5 not mentally 
prepared, 3 completed therapy early, 2 due to 
distress, 1 non engagement) 
Allocated to Immediate (n = 21)
Received allocated intervention (n = 21)
Did not receive allocated intervention 
(withdrawal before initial session) (n = 1)
Lost to follow-up (n = 2; unable to contact)
Discontinued intervention (n = 6; 2 non 
engagement, 1 no availability, 1 physical 
health concern, 1 unable to attend, 1 
completed therapy early) 
Allocated to Waiting List (n = 21)
Received allocated intervention (n = 21)
Did not receive allocated intervention (give 
reasons) (n = 0)
Analysed  (n = 21)
Excluded from analysis (n = 0)
Allocaon
Analysis
Follow -Up
Randomized (n = 42)
Enrolment
Fig. 1. CONSORT flow diagram.
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Table 1. Demographics and clinical characteristics
Arm
TotalImmediate Delayed
N %/Mean|SD n %/Mean|SD n %/Mean|SD
Age 21 40.2 10.13 21 44.0 11.97 42 42.1 |11.12
Time since trauma (months) 21 191.2 145.42 21 271.4 186.42 42 231.3|170.05
Ethnic origin White British 21 100 19 90.5 40 95.2
Any other Mixed/multiple ethnic background 0 0 1 4.8 1 2.4
African 0 0 1 4.8 1 2.4
Highest level of qualification No qualifications 0 0.0 1 5.0 1 2.6
1-4 GCSEs or equivalent 7 36.8 6 30.0 13 33.3
5 + GCSEs or equivalent 7 36.8 3 15.0 10 25.6
Apprenticeship 0 0.0 1 5.0 1 2.6
2 + A Levels or equivalent 1 5.3 4 20.0 5 12.8
Degree level or above 4 21.1 5 25.0 9 23.1
Other qualifications 0 0.0 0 0.0 0 0.0
Current employment status Employed 4 19.0 10 50.0 14 34.1
Self-employed or freelance 1 4.8 2 10.0 3 7.3
Been made redundant 1 4.8 0 0.0 1 2.4
Homemaker 1 4.8 0 0.0 1 2.4
Retired 3 14.3 1 5.0 4 9.8
Volunteering 3 14.3 0 0.0 3 7.3
Unable to work 8 38.1 7 35.0 15 36.6
Diagnosis of depressive disorder No 11 52.4 12 57.1 23 54.8
Yes 10 47.6 9 42.9 19 45.2
Table 2. Primary and secondary outcome mean (SD) scores at all time points
Time point
Baseline Week 12 Week 26
n Mean SD n Mean SD N Mean SD
CAPS-5 Immediate 21 48.5 8.39 16 30.8 17.09 17 30.8 18.30
Delayed 21 47.6 7.05 19 40.8 10.80 19 29.5 17.67
Total 42 48.0 7.67 35 36.3 14.71 36 30.1 17.72
PCL-5 Immediate 21 58.0 7.22 14 46.1 16.57 12 39.4 22.80
Delayed 21 60.0 9.83 15 59.0 5.98 17 48.2 17.90
Total 42 59.0 8.58 29 52.8 13.73 29 44.6 20.17
WSAS Immediate 21 26.6 5.86 14 24.6 9.25 12 18.8 13.17
Delayed 21 24.7 8.00 15 25.1 7.91 17 17.7 11.56
Total 42 25.6 6.99 29 24.8 8.43 29 18.2 12.03
PHQ-9 Immediate 21 17.1 5.14 13 14.8 6.14 13 14.1 8.26
Delayed 21 17.2 5.70 15 17.5 5.67 17 14.3 6.01
Total 42 17.2 5.36 28 16.3 5.95 30 14.2 6.94
GAD-7 Immediate 21 14.6 3.94 14 10.6 5.40 12 12.3 6.83
Delayed 21 16.6 4.42 15 15.1 5.13 17 13.3 5.64
Total 42 15.6 4.25 29 12.9 5.66 29 12.9 6.06
ISI Immediate 21 19.8 6.43 14 13.4 5.99 12 14.7 9.00
Delayed 21 20.0 5.19 15 21.7 4.94 17 19.6 6.00
Total 42 19.9 5.77 29 17.7 6.84 29 17.6 7.65
EQ-5D-5L* Immediate 21 0.54 0.25 14 0.52 0.33 12 0.47 0.41
Delayed 20 0.44 0.28 15 0.46 0.26 17 0.51 0.27
Total 41 0.49 0.27 29 0.49 0.29 29 0.49 0.33
AUDIT-O Immediate 21 7.3 9.29 14 6.8 9.41 12 5.8 9.50
Delayed 21 7.9 5.64 15 5.7 5.21 17 8.2 8.56
Total 42 7.6 7.59 29 6.2 7.41 29 7.2 8.88
MSPSS Immediate 21 47.0 12.50 14 52.9 14.82 12 54.3 20.89
Delayed 21 55.3 19.59 15 58.9 19.85 17 55.8 19.20
Total 42 51.1 16.77 29 56.0 17.56 29 55.2 19.56
*Crosswalk to EQ-5D-3L UK Value Index.
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hope about being helped) and poorly to 3MDR
(e.g. missing sessions, voicing anxieties). Table S2
summarizes findings across all interviewees. Inter-
view data generated with both veterans and thera-
pists revealed 3MDR to be a complex, powerful,
intervention. For those engaging in 3MDR it
involved much more than just the time spent on
the treadmill, encompassing the initial time spent
learning about what 3MDR involves, followed by
locating images and music alone or in the company
of others. It often included significant travel before
the therapy sessions and being supported by
others, where necessary, outside of the clinic.
Therapist views on the importance of psychoso-
cial stability and support outside of the clinic were
a key theme. Veterans’ descriptions of how chal-
lenging it was to select images and music suggested
a potential for specific support at this earliest
stage. Therapeutic continuity may be helped by
3MDR being provided by therapists already
known to patients, but views on the absolute
importance of this were mixed. The focus 3MDR
Table 3. Primary and secondary outcome analyses for differences at week 12
Time point
Diff in means 95% confidence interval P-value
Immediate Delayed
n Mean SD n Mean SD
CAPS-5 Baseline 16 47.0 8.63 19 47.6 7.34 9.561 17.147 to 1.974 0.014
Week 12 16 30.8 17.09 19 40.8 10.80
PCL-5 Baseline 14 57.3 7.06 15 59.4 9.42 11.667 20.063 to 3.271 0.006
Week 12 14 46.1 16.57 15 59.0 5.98
WSAS Baseline 14 26.4 5.65 15 24.5 8.58 1.196 6.565 to 4.173 0.662
Week 12 14 24.6 9.25 15 25.1 7.91
PHQ-9 Baseline 13 16.8 5.26 15 16.2 5.47 3.045 6.610 to 0.520 0.094
Week 12 13 14.8 6.14 15 17.5 5.67
GAD-7 Baseline 14 13.9 3.94 15 15.6 4.69 5.143 9.421 to 0.864 0.018
Week 12 14 10.6 5.40 15 15.1 5.13
ISI Baseline 14 19.6 6.95 15 19.3 5.33 7.344 10.643 to 4.045 <0.001
Week 12 14 13.4 5.99 15 21.7 4.94
EQ-5D-5L* Baseline 14 0.57 0.26 15 0.46 0.26 0.055 0.211 to 0.101 0.490
Week 12 14 0.52 0.33 15 0.46 0.25
AUDIT-O Baseline 14 6.1 9.57 15 5.4 3.89 0.139 1.738 to 2.016 0.843
Week 12 14 6.8 9.41 15 5.7 5.21
MSPSS Baseline 14 48.1 13.14 15 56.7 21.71 0.086 10.045 to 10.218 0.987
Week 12 14 52.9 14.82 15 58.9 19.85
Bold has been used to highlight results that were statistically significant at the a = 0.05 level.
Model covariates: baseline version of outcome, age, baseline PHQ-9 (for comorbidity of depression)[removed for analysis of PHQ-9 as an outcome else duplicated from before]
and time since trauma (in months).
Difference in means between randomization arms: delay is the reference.
*Crosswalk to EQ-5D-3L UK Value Index.
Fig. 2. Mean CAPS-5 over time by
randomization arm following
imputation at Weeks 12 and 26.
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has on walking, and its use of visual and auditory
stimuli, may place less of a premium on the inter-
personal than do other therapies, helping explain
some therapists’ use of the term ‘coaching’ to
describe the work that they did.
Both groups of interviewees spoke of the sur-
rounding context for the provision and receipt of
3MDR, including the location of the clinic and tra-
vel. Accurate information on parking arrange-
ments and on how to find the clinic is examples of
small actions able to make a difference, along with
information on how 3MDR treatment sessions can
cause a loss of attention and how being accompa-
nied to and from therapy were important. Out of
hours support was important for some veterans,
particularly those experiencing increased symp-
toms, and therapists observed how some people
dropping out included those whose personal lives
were complex.
For therapists, clarity on the theory underpin-
ning 3MDR was important, along with developing
expertise in providing the therapy without having
to over-rely on a printed protocol. Related to this
was knowing how far 3MDR practices might be
augmented through drawing on other bodies of
skill and knowledge, such as might be deployed in
the post-therapy debriefing component of sessions.
Agreement on the parameters of practice may be
an important consideration in the future, along
with guidance relating to the number of treatments
available to each participant and the use of images
within individual sessions. With some exceptions,
there was broad agreement across all those inter-
viewed that six sessions may not be enough and
that therapist ‘flex’ could usefully include making
judgments on treatment duration up to a specified
maximum. Therapists also spoke of the benefits of
having latitude over the sequencing and, poten-
tially, the number of images used in individual ses-
sions.
Discussion
Main results
This trial confirms that 3MDR can reduce trau-
matic stress symptoms in military veterans with
treatment-resistant service-related PTSD. The
mean difference in CAPS5 score of 9.56 points
between the two arms at 12 weeks is likely to be
clinically significant and represents a 19% reduc-
tion in PTSD compared with the baseline mean. It
is noteworthy that being on the waitlist resulted in
a mean 6.8 point drop on the CAPS5 at 12 weeks,
suggesting some form of positive impact at the
prospect of treatment in individuals with hitherto
treatment refractory symptoms. The total reduc-
tion pre- and post-treatment of those receiving
3MDR immediately of 17.7 points on the CAPS5
represents a clear, clinically relevant 37% reduc-
tion in PTSD symptoms from presentation that
was maintained at 26-week follow-up. The waitlist
group improved to a similar degree once they had
received 3MDR.
The positive impact of 3MDR on the secondary
outcome measures of anxiety and insomnia is
encouraging and is consistent with studies of other
successful treatments for PTSD, suggesting gener-
alization of positive effects to other groups of
symptoms (25). The absence of effect on alcohol
use is not surprising as those included did not
report significant substance misuse problems at
baseline. Improvement for functioning, depression,
health-related quality of life and increased per-
ceived social support measures are often reported
following effective treatment for PTSD (25) but
are not seen here, potentially due to the numbers
available. A future, larger Phase III trial may or
may not see these improvements.
Acceptability
3MDR was found to be acceptable to most, but
not all, participants. Data from the nested process
evaluation suggested several factors that may
impact efficacy and successful roll-out of 3MDR.
These included the appropriate assessment and
selection of potential candidates for 3MDR,
enhanced preparation in advance of 3MDR, the
number of treatment sessions available, ability to
tolerate the effect of exposure, support between
sessions and greater flexibility with respect to con-
tent of later sessions. A number of participants
and therapists felt that more sessions either on the
platform or to help integrate/facilitate the platform
work would have been beneficial. Several thera-
pists felt that some trauma-focused psychological
treatment after the platform sessions would have
resulted in greater improvement for some partici-
pants. Further work is underway with data gener-
ated from the trial to help with the refinement of
selection criteria for 3MDR.
Mechanism of action
It is difficult to draw mechanistic conclusions from
the trial; the potential mechanisms were included
in this version of the intervention, but none of
them were specifically isolated and tested so all
remain speculative. 3MDR is clearly a complex
intervention, and it is not known exactly how it
works; dismantling studies would be required to
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determine this. The results appear to support the
combination of elements involved in 3MDR and
Van Gelderen et al’s (26) model for 3MDR. The
model proposes that virtual reality increases pres-
ence and attention during treatment to facilitate
memory retrieval with the pictures and music per-
sonalizing the experience. Walking towards cues of
the traumatic memories is felt to decrease avoid-
ance, with bilateral stimulation requiring dual
attention postulated to further facilitate new learn-
ing and reconsolidation. Novel elements of the
intervention, absent from many standard PTSD
treatments, including activation and personaliza-
tion, are also recognized as potentially beneficial.
Results in the context of other research
There is limited existing research into treatment-re-
sistant PTSD and even more limited significant
advances. Emerging work with MDMA-assisted
psychotherapy shows promise (27) but is unlikely
to be appropriate for all people with treatment-re-
sistant PTSD. Pharmacological augmentation
strategies have had modest success (28) but have
not achieved the step change required. Results
from meta-analyses undertaken for the 2018 Inter-
national Society for Traumatic Stress Studies
(ISTSS) prevention and treatment guidelines (29)
found a number of novel treatments to have
emerging evidence of effect in individuals who had
already tried other treatments (e.g. neurofeedback
and transcranial magnetic stimulation (TMS)).
The only other early-phase randomized con-
trolled trial of 3MDR, conducted by the origina-
tors of 3MDR in the Netherlands (30), was also
positive and taken together with our trial point to
the potential effectiveness of 3MDR and its posi-
tion as a major candidate for further evaluation.
The effect sizes found place 3MDR on a level with
neurofeedback and TMS, as more complicated
treatments with emerging evidence of effect for
PTSD in people with more treatment-resistant
forms of PTSD. If 3MDR does prove to be effec-
tive, this would result in an additional option of
treatment for people with PTSD at a point when,
currently, effective active treatment possibilities
are often exhausted and the prospects of further
recovery low.
Strengths and limitations
This was a well-designed RCT that adhered to cur-
rent methodological recommendations for this
type of work. A risk of bias assessment for the trial
against the Cochrane Risk of Bias checklist (31)
confirmed a low risk of bias that compares very
favourably with and is superior to the vast major-
ity of randomized controlled trials of treatments
for PTSD (see Table S3). Blinding of participants
and personnel (performance bias) was the only risk
rated high, as is true for almost all psychological
treatment trials; the participants and therapists
could not be blinded to the fact the individuals in
the immediate 3MDR group were receiving
3MDR. The outcome raters demonstrated good
inter-rater reliability based on training videos, but
it is a limitation that this was not tested with videos
of trial participant assessments.
It is important that the limited scale (42 partici-
pants) of this trial is acknowledged when drawing
inferences from the results. A major strength of
the trial was the careful training and supervision
of the therapists, along with fidelity checks
demonstrating good adherence to the 3MDR
treatment protocol. That said, a number of the
therapists reported gaining confidence as they
treated more participants and it may be that ear-
lier participants could have done better if treated
when the therapists had more confidence and
experience with the technique. A limitation is that
fidelity ratings were not independently re-rated for
reliability.
Another key strength of the trial was the utiliza-
tion of both quantitative and qualitative
approaches and the ability to cross-reference
results from different sources to corroborate or
challenge outcomes. The quantitative and qualita-
tive results were consistent, which strengthens the
belief that the results are likely to provide a true
reflection of the efficacy of 3MDR.
The significant improvement in members of the
delayed treatment arm before they received 3MDR
does make interpretation more difficult than if
there had been no response. It is always difficult to
identify a perfect control condition, and it may
have been that no treatment at all would have pro-
vided a better estimate of the absence of treatment
at all. This was, however, not felt to be ethically
optimal for this trial, and the cross-over design
also provided additional information that has been
helpful, not least the further improvement post-
3MDR in the delayed treatment group. We
demonstrated that the intervention effect was sub-
stantially larger than and significantly more than
the effect of providing hope.
Clinical implications
Because of the preliminary nature of this work, it
would be premature to recommend 3MDR for
routine clinical practice. If the effects suggested by
this trial were to be replicated and then successfully
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implemented, thousands more people with PTSD
would recover and the availability of 3MDR
would herald a new era in the evidence-based care
options available to people with PTSD. A more
portable version of the system required to deliver
3MDR is now available, which should improve the
potential for more affordable, scalable implemen-
tation in the future.
Research implications
The main research implication is the desirability of
a pragmatic Phase III effectiveness trial of 3MDR.
This trial only included military veterans with
PTSD secondary to service-related experience.
There is no reason to believe that non-military vet-
erans would not benefit from 3MDR, and anecdo-
tal evidence is emerging that 3MDR can help
people with PTSD to non-military trauma but this
remains an empirical question and one that needs
research to determine it. Future evaluation could
be enhanced by considering the inclusion of heart
rate variability or other biological markers to cor-
roborate symptom severity improvement.
The actual mechanism of 3MDR remains
unclear and studies would be required with differ-
ent designs, including dismantling studies, to shed
more light on this. 3MDR is a complex interven-
tion with a number of different elements, and it
is not possible to say what is and what is not
required at present. The number of 3MDR ses-
sions requires more scrutiny; the results of this
trial suggest that more sessions are likely to be
needed for some individuals, and some individu-
als may benefit from booster sessions if their
symptoms relapse. It is also unclear as to what
the nature of additional sessions should be, and
there is a need to further evaluate key issues such
as optimal levels of support and the characteris-
tics of people with PTSD most likely to benefit
from 3MDR. The ability to walk a reasonable
distance was a requirement for this study, and
adaptation of 3MDR for other forms of locomo-
tion such as cycle or wheelchair ergometer would
be desirable in order to treat people who have
difficulty walking.
In addition to considering clinical effectiveness,
cost-effectiveness work is required. 3MDR is an
expensive intervention; the equipment is costly,
and it is resource intensive in terms of therapist
time and additional support. Therefore, any effec-
tiveness trial should include a health economic
evaluation to allow informed choices to be made in
the future with respect to funding and adoption by
clinical services.
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